Table 4.
Significant variables associated with latent tuberculosis infection (LTBI) stratified by tuberculin skin test (TST) or interferon-gamma release assays in 302 HIV-infected patients with no past or current tuberculosis (TB) nor LTBI
| |
TST positive |
QFG or T-SPOT.TB |
Either TST, QFG or T-SPOT.TB |
All tests (TST, QFG and T.SPOT.TB (Mc) negative |
|---|---|---|---|---|
| |
(n = 20) * |
(Mc) positive |
(Mc) positive |
|
| (n = 45) ** | (n = 56) *** | (n = 246) | ||
| Median CD4 cell/μl count (range) |
630 (90-1650)† |
580 (10-1740) ‡ |
580 (10-1730) † |
450 (10-1760) |
| CD4 cell count < 350/μl |
4 (20) |
9 (20)¢ |
13 (23.2) |
88 (35.8) |
| CD4 cell count < 500/μl |
6 (30) |
12 (26.5) ‡ |
18 (32.1) § |
135 (54.9) |
| Median time (year) from 1st HIV-positive test (range) |
11.5 (0.1-27) †† |
12 (0.1-25) c |
12 (0.1-27) †† |
9.5 (0.1-23) |
| Contact with patients with TB |
13 (65) § |
4 (8.9) |
24 (42.9) †† |
69 (28.2) |
| History of injection drug use |
15 (75) † |
24 (53.3) |
33 (58.8) †† |
105 (42.7) |
| History of prior prison stay |
12 (60) ‡ |
24 (53.3) |
21 (37.1) § |
39 (17.9) |
| Lived in a shelter or homeless |
11 (55) ‡ |
10 (25.2) |
18 (32.1) |
48 (19.5) |
| Hepatitis C virus co-infection | 14 (70) ¢ | 20 (44.5) | 28 (50.0) | 92 (37.7) |
NOTE. Data are no (%) of patients unless otherwise indicated.
ART, antiretroviral therapy; BCG, Bacille Calmette-Guérin; QFG, QuantiFERON-TB Gold, Mc: Manufacturer’s interpretation criteria.
The numbers printed in bold letters indicate the value of variables significantly associated with positive test results in univariate analyses: †† p = 0.04; † p = 0.02 § p = 0.002; ¢ p = 0.009; ‡ p < 0.001; * comparing TST positive (n = 20) with TST negative patients (n = 282); ** comparing QFG or T.SPOT.TB positive (n = 45) with QFG or T.SPOT-TB (Mc) negative patients (n = 257); *** comparing either TST, QFG or T-SPOT.TB (Mc) positive (n = 56) with all tests (TST, QFG and T.SPOT.TB-Mc) negative (n = 246).